2024 Laboratory Reimbursement Trends and What to Expect in 2025
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
Deciding whether to purchase or lease laboratory instrumentation involves a variety of factors.
Release of second-generation Cologuard test data and recently announced partnerships aim to position company well for the future.
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.
In the first half of this year, US companies have cut the second-highest total of jobs since 2009, according to a recent report.
A recent SCOTUS ruling on a healthcare fraud case could help defend labs against baseless whistleblower cases.
Labs will have to submit Z-Codes with every molecular pathology testing code billed to UnitedHealthcare, starting Aug. 1.
Last month’s key cases involved the outcome of a UHC lawsuit and fines for misleading claims about a COVID-19 test.
Individualized quality control plans offer flexibility and the capacity to seamlessly adopt new nonwaived tests, practices, and technologies.
Recently released Centers for Medicare and Medicaid Services guidance shares when CLIA regulations apply to international labs.
Federal lawmakers have renewed efforts to pass legislation ensuring Medicare coverage of multi-cancer early detection (MCED) tests.